Background Anlotinib demonstrated improved overall survival (OS) and progression-free
survival (PFS) compared with placebo as a third-line or subsequent therapy in patients with …

Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …

Background Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303
trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell …

9573 Background: Anti-angiogenic monoclonal antibodies plus EGFR TKIs have previously
shown to prolong PFS in patients with EGFR-mutated NSCLC (JO25567 and NEJ026) …

Background Anlotinib showed significant survival benefits in advanced non‐small cell lung
cancer (NSCLC) patients as a third‐or further‐line treatment in the ALTER0303 trial. We …

Background Anlotinib hydrochloride, an oral tyrosine kinase inhibitor targeting VEGFR,
FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated …

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer
and its incidence seriously affects human health. The purpose of this study was to evaluate …

Objective: To evaluate the efficacy and safety of anlotinib in patients with advanced non-
small cell lung cancer (NSCLC). Methods: Patients with stage ⅢB/Ⅳ NSCLC who …